Vaxent Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $3.94M
Latest Deal Amount
  • Investors
  • 3

Vaxent General Information

Description

Developer of sub-unit vaccines designed to fight against group A streptococcus that causes pharyngitis and strep throat in children. The company's vaccines are used in the treatment of various infectious diseases that have been tested in early-stage human clinical trials to advance its lead product in clinical testing, enabling patients to develop immunity against infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • Memphis, TN 37501
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxent Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 20-Jul-2017 $3.94M 0000 Completed Clinical Trials - General
4. Debt - General 23-Mar-2015 0000 Completed Clinical Trials - General
3. Debt - General 06-Nov-2009 0000 Completed Clinical Trials - General
2. Early Stage VC (Series A) 24-Jun-2008 $50K $50K Completed Clinical Trials - General
1. Accelerator/Incubator 01-Apr-2008 Completed Startup
To view Vaxent’s complete valuation and funding history, request access »

Vaxent Executive Team (2)

Name Title Board Seat Contact Info
James Dale MD Co-Founder, Chief Scientific Officer & Chief Technology Officer
You’re viewing 1 of 2 executive team members. Get the full list »

Vaxent Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Innova Memphis Venture Capital Minority 000 0000 000000 0
Memphis Bioworks Foundation Not-For-Profit Venture Capital 000 0000 000000 0
To view Vaxent’s complete investors history, request access »